Aging Clinical Trial
— DARTOfficial title:
The DART Study: Exercise Strategies to Improve Physical Function in Older Adults
Verified date | September 2020 |
Source | Ohio University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effect of three different exercise strategies on physical function in older adults. Participants will be randomly assigned to one of three exercise groups: resistance training, moderate-intensity continuous cycling on a stationary bicycle, and high-intensity interval training on a stationary bicycle.
Status | Suspended |
Enrollment | 30 |
Est. completion date | September 30, 2021 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age 60-75 years with no significant health issues or conditions that, in the investigator's opinion, would limit the subject's ability to complete the study per protocol or that would impact the capability to get an accurate measurement of study endpoints. - Body mass index between 18.0 and 35 kg/m2. - Willingness to maintain current diet and adhere to the intervention programs described for the study and willing to undergo all testing procedures. - Able to read, understand, and complete study-related questionnaires - Able to read and understand, and willing to sign the informed consent form (ICF). - 6-minute walk distance of 450-725 meters for men and 400-675 meters for women. Exclusion Criteria: - Failure to provide informed consent. - 6-minute walk distance below 450 meters or above 725 meters for men, below 400 meters or above 675 meters for women - Any activities of daily living (ADL) disability (difficulty feeding, dressing, continence, bathing, toileting, and transferring). - Lives in a nursing home or assisted living facility - Known neuromuscular or neurological conditions affecting somatosensory or motor function or control (e.g., hemiplegia, multiple sclerosis, peripheral neuropathy, Parkinsons disease, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, etc.). - Unable to communicate because of severe hearing loss or speech disorder. - Severe visual impairment, which would preclude completion of the assessments. - Cancer requiring treatment currently or in the past 2 years (except primary non-melanoma skin cancer or in situ cervical cancer) - Hospitalization (medical confinement for 24 hours), or immobilization, or major surgical procedure requiring general anesthesia within 12 weeks prior to screening, or any planned surgical procedures during the study period. - Chronic or relapsing/remitting gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome. - Known history of human immunodeficiency virus (HIV) antibody at screening. - Use of systemic glucocorticoids. - Any history of angina pectoris - Any history of heart failure - Any history of myocardial infarction - Any coronary artery bypass graft or percutaneous coronary intervention - Heart disease that limits exercise (valvular, congenital, ischaemic and hypertrophic cardiomyopathy) - Complex ventricular arrhythmias or heart block - Chronic obstructive pulmonary disease, cerebrovascular disease, or peripheral vascular disease - Diabetes mellitus - Severe neuropathy - Mini-mental state exam score (MMSE) below 19 - Psychiatric conditions that warrant acute or chronic therapeutic intervention (e.g., major depressive disorder, bipolar disorder, panic disorder, schizophrenia) that in the investigators opinion may interfere with the conduct of study procedures - Unable to undergo magnetic resonance imaging (MRI) (e. g. body containing any metallic medical devices or equipment, including heart pacemakers, metal prostheses, implants or surgical clips, any prior injury from shrapnel or grinding metal, exposure to metallic dusts, metallic shavings or having tattoos containing metallic dyes). - Unable to reliably undergo exercise or strength tests described for this study. - Participation in progressive resistance exercise 2 or more days/week for most weeks over the 24 weeks prior to screening, OR 150+ minutes of accumulated aerobic exercise each week for most weeks over the 24 weeks prior to screening. - Current self-reported activity level that, in the investigator's opinion, is considered highly active for older adults - Participation in any clinical trial within 12 weeks prior to screening. - Limb amputation (except for toes) and/or any fracture within 24 weeks. - Any disorder that will not allow completion of the motions required for resistance or aerobic exercise - Conditions (such as myasthenia gravis, myositis, muscular dystrophy or myopathy, including drug-induced myopathy) leading to muscle loss, muscle weakness, muscle cramps or myalgia. - Acute viral or bacterial upper or lower respiratory infection at screening - Abnormal or uncontrolled blood pressure (BP) at the screening visit defined as BP > 170/100 mmHg. If taking anti-hypertensive medication, have to be on stable doses of medication for more than 3 months. - Current or recent history (within 1 year of screen) of heavy alcohol consumption or drug abuse that in the investigators opinion may interfere with the conduct of study procedures. - Reports being pregnant, lactating, or that they anticipate becoming pregnant in the next 3-months. If a woman becomes pregnant while on study protocol they will be withdrawn from the study Prohibited Medications: Medications that, in the PIs opinion, would confound study integrity by interacting with study outcomes. For instance: - Anti-obesity drugs, nutraceuticals, and dietary supplements that may affect body mass and body composition. - Any drug or supplement known to influence muscle mass or performance including but not limited to anabolic steroids, insulin-like growth factor 1 (IGF-1), growth hormone (GH), replacement androgen therapy, anti-androgen therapy. |
Country | Name | City | State |
---|---|---|---|
United States | Ohio University | Athens | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio University | American Heart Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximal Oxygen Consumption | The primary endpoint is maximal oxygen consumption measured by both relative and absolute changes in maximal oxygen consumption obtained during a graded exercise test on a cycle ergometer. | Change from baseline at 12 weeks | |
Primary | Knee extensor isokinetic power | Maximal muscle power (maximal torque in foot-pounds) of the quadriceps using an isokinetic dynamometer | Change from baseline at 12 weeks | |
Secondary | Knee extensor isometric force production | Maximal muscle strength of the quadriceps (in foot-pounds) as measured by an isometric dynamometer | Change from baseline at 12 weeks | |
Secondary | Knee extensor isokinetic endurance | Total power output (cumulative torque in foot-pounds) produced from 120 consecutive maximal knee extensions using an isokinetic dynamometer | Change from baseline at 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |